Equities

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.41
  • Today's Change0.600 / 8.81%
  • Shares traded136.00
  • 1 Year change-89.99%
  • Beta1.0403
Data delayed at least 15 minutes, as of Sep 19 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

  • Revenue in USD (TTM)184.34m
  • Net income in USD-897.68m
  • Incorporated2021
  • Employees1.22k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DNA:NYQ since
announced
Transaction
value
Proof Diagnostics IncDeal completed28 Feb 202428 Feb 2024Deal completed384.31%--
Patch Biosciences IncDeal completed26 Feb 202426 Feb 2024Deal completed461.36%--
Reverie Labs IncDeal completed23 Feb 202423 Feb 2024Deal completed461.36%--
Data delayed at least 15 minutes, as of Sep 19 2024 00:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jasper Therapeutics Inc0.00-62.44m343.49m45.00--3.42-----5.10-5.100.006.640.00----0.00-52.45---57.00--------------0.00-------71.06------
Lyell Immunopharma Inc54.00k-210.26m345.60m224.00--0.6099--6,400.08-0.8297-0.82970.00022.210.00007----241.07-28.23---29.53-------389,368.50------0.00---99.85---28.13------
Aldeyra Therapeutics Inc0.00-37.87m348.80m10.00--3.55-----0.6387-0.63870.001.650.00----0.00-26.89-36.79-31.76-40.77------------0.1342------39.47------
Alto Neuroscience Inc-100.00bn-100.00bn355.86m78.00--1.98----------6.67----------------------------0.053-------31.02------
AC Immune SA18.30m-71.51m359.15m133.00--2.47--19.62-0.7584-0.75840.19771.470.0787--28.76137,616.50-30.73-18.25-42.90-19.52-----390.68-148.29---128.010.0255--276.1415.5223.35---15.49--
Nautilus Biotechnology Inc0.00-69.64m359.93m164.00--1.53-----0.557-0.5570.001.880.00----0.00-23.08---23.73--------------0.00-------9.93------
Inozyme Pharma Inc0.00-88.56m364.49m59.00--3.82-----1.46-1.460.001.520.00----0.00-57.76-45.00-63.48-48.90------------0.3244-------6.13--2.85--
Monte Rosa Therapeutics Inc5.76m-130.41m365.17m103.00--1.62--63.41-2.24-2.240.09673.660.0185--1.0543,300.75-41.88---46.47-------2,264.53------0.00-------24.75------
Nkarta Inc0.00-107.91m371.84m150.00--0.8205-----2.01-2.010.006.420.00----0.00-21.95-32.39-23.07-34.05-------372,519.20----0.00-------3.22--106.05--
Organogenesis Holdings Inc448.39m-16.54m377.84m862.00--1.43--0.8427-0.125-0.1253.381.991.004.274.49520,176.30-3.705.46-4.516.9075.1474.94-3.694.812.428.330.20010.00-3.9417.49-68.16--67.34--
Northwest Biotherapeutics Inc1.65m-75.55m384.46m25.00------233.71-0.0644-0.06440.0014-0.0470.0581----65,800.00-260.06-381.58---------4,479.03-6,479.25---14.10----14.8036.2138.71--77.88--
Ginkgo Bioworks Holdings Inc184.34m-897.68m389.58m1.22k--4.59--2.11-18.03-18.033.691.620.0941--4.20151,342.40-45.83---50.04--80.22---486.98------0.00---47.36--57.58------
GH Research PLC-100.00bn-100.00bn415.70m49.00--2.09----------3.82----------------------------0.0038-------58.47------
iTeos Therapeutics Inc35.00m-108.14m423.29m157.00--0.6376--12.09-3.00-3.000.951718.180.0481--1.52222,929.90-14.865.84-15.557.02-----308.9622.09----0.000.00-95.29---216.54--68.45--
Instil Bio Inc0.00-119.58m429.91m49.00--2.20-----18.39-18.390.0029.980.00----0.00-34.04---35.48--------------0.2958------30.06------
Grail Inc109.74m-2.88bn431.89m1.37k--0.1603--3.94-99.94-99.943.9186.80------81,894.77---47.45---48.5544.06---2,627.35-5,118.86----0.00--67.61--72.85---4.22--
Data as of Sep 19 2024. Currency figures normalised to Ginkgo Bioworks Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

37.80%Per cent of shares held by top holders
HolderShares% Held
Viking Global Investors LPas of 30 Jun 20243.58m8.30%
The Vanguard Group, Inc.as of 30 Jun 20243.43m7.97%
Baillie Gifford & Co.as of 30 Jun 20243.36m7.80%
Anchorage Capital Group LLCas of 30 Jun 20241.75m4.05%
BlackRock Fund Advisorsas of 30 Jun 2024971.63k2.25%
Two Sigma Advisers LPas of 30 Jun 2024786.09k1.82%
Legal & General Investment Management Ltd.as of 30 Jun 2024671.70k1.56%
Glenview Capital Management LLCas of 30 Jun 2024662.50k1.54%
ARK Investment Management LLCas of 30 Jun 2024596.28k1.38%
Two Sigma Investments LPas of 30 Jun 2024485.27k1.13%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.